On release of the original announcement on 15th December 2020 entitled 'Mesoblast Phase 3 Chronic Heart Failure Results' back in December, the share price dropped 20% from $4.54 to $3.64 prior to the announcement entitled 'Mesoblast Update on COVID-19 ARDS Trial' that was released on 18th December 2020.
A recent low of $2.10 followed by consolidation between $2.15 to $2.30 suggests MSB found price support at these levels. The current price of $2.63 is a 21% rise from the recent low of $2.16 that was observed immediately prior to the announcement entitled 'Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF'. Hence I am of the opinion that we won't see much more upside from this announcement until something else happens.
A worldwide CHF agreement would in my opinion create a base of $5 immediately.
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-382
-
- There are more pages in this discussion • 382 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |